Program in Pharmaceutical Sciences and Pharmacogenomics, University of California, San Francisco, San Francisco, Calif; Department of Bioengineering & Therapeutic Sciences, University of California, San Francisco, San Francisco, Calif.
Department of Medicine, University of California, San Francisco, San Francisco, Calif.
J Allergy Clin Immunol. 2019 Mar;143(3):957-969. doi: 10.1016/j.jaci.2016.08.057. Epub 2018 Sep 7.
Asthma is a common but complex disease with racial/ethnic differences in prevalence, morbidity, and response to therapies.
We sought to perform an analysis of genetic ancestry to identify new loci that contribute to asthma susceptibility.
We leveraged the mixed ancestry of 3902 Latinos and performed an admixture mapping meta-analysis for asthma susceptibility. We replicated associations in an independent study of 3774 Latinos, performed targeted sequencing for fine mapping, and tested for disease correlations with gene expression in the whole blood of more than 500 subjects from 3 racial/ethnic groups.
We identified a genome-wide significant admixture mapping peak at 18q21 in Latinos (P = 6.8 × 10), where Native American ancestry was associated with increased risk of asthma (odds ratio [OR], 1.20; 95% CI, 1.07-1.34; P = .002) and European ancestry was associated with protection (OR, 0.86; 95% CI, 0.77-0.96; P = .008). Our findings were replicated in an independent childhood asthma study in Latinos (P = 5.3 × 10, combined P = 2.6 × 10). Fine mapping of 18q21 in 1978 Latinos identified a significant association with multiple variants 5' of SMAD family member 2 (SMAD2) in Mexicans, whereas a single rare variant in the same window was the top association in Puerto Ricans. Low versus high SMAD2 blood expression was correlated with case status (13.4% lower expression; OR, 3.93; 95% CI, 2.12-7.28; P < .001). In addition, lower expression of SMAD2 was associated with more frequent exacerbations among Puerto Ricans with asthma.
Ancestry at 18q21 was significantly associated with asthma in Latinos and implicated multiple ancestry-informative noncoding variants upstream of SMAD2 with asthma susceptibility. Furthermore, decreased SMAD2 expression in blood was strongly associated with increased asthma risk and increased exacerbations.
哮喘是一种常见但复杂的疾病,其流行程度、发病率和对治疗的反应在不同种族/民族之间存在差异。
我们试图进行遗传血统分析,以确定导致哮喘易感性的新基因座。
我们利用 3902 名拉丁裔的混合血统进行了哮喘易感性的混合映射荟萃分析。我们在一项独立的 3774 名拉丁裔研究中复制了关联,进行了精细映射的靶向测序,并测试了超过 500 名来自 3 个种族/民族群体的个体的全血中基因表达与疾病的相关性。
我们在拉丁裔人群中发现了一个全基因组显著的混合映射峰,位于 18q21(P=6.8×10-8),其中美洲原住民血统与哮喘风险增加相关(优势比[OR],1.20;95%可信区间,1.07-1.34;P=0.002),而欧洲血统与保护相关(OR,0.86;95%可信区间,0.77-0.96;P=0.008)。我们的发现在另一项拉丁裔儿童哮喘的独立研究中得到了复制(P=5.3×10-7,联合 P=2.6×10-10)。对 1978 名拉丁裔人群的 18q21 精细作图发现,在墨西哥人群中,SMAD 家族成员 2(SMAD2)5'端的多个变异与该区域显著相关,而在波多黎各人中,同一窗口的单个罕见变异是最相关的。低与高 SMAD2 血液表达与病例状态相关(表达降低 13.4%;OR,3.93;95%可信区间,2.12-7.28;P<0.001)。此外,在患有哮喘的波多黎各人中,SMAD2 表达水平较低与更频繁的恶化有关。
18q21 的血统与拉丁裔人群中的哮喘显著相关,并提示 SMAD2 上游的多个与血统相关的非编码变异与哮喘易感性有关。此外,血液中 SMAD2 表达的降低与哮喘风险的增加和恶化的增加密切相关。